The journal of nutrition, health & aging

, Volume 17, Issue 7, pp 612–618 | Cite as

Designing pharmaceutical trials for sarcopenia in frail older adults: EU/US task force recommendations

  • B. Vellas
  • M. Pahor
  • T. Manini
  • D. Rooks
  • J. M. Guralnik
  • J. Morley
  • S. Studenski
  • W. Evans
  • C. Asbrand
  • R. Fariello
  • S. Pereira
  • Y. Rolland
  • G. Abellan Van Kan
  • M. Cesari
  • W. M. C. Chumlea
  • R. Fielding


An international task force of academic and industry leaders in sarcopenia research met on December 5, 2012 in Orlando, Florida to develop guidelines for designing and executing randomized clinical trials of sarcopenia treatments. The Task Force reviewed results from previous trials in related disease areas to extract lessons relevant to future sarcopenia trials, including practical issues regarding the design and conduct of trials in elderly populations, the definition of appropriate target populations, and the selection of screening tools, outcome measures, and biomarkers. They discussed regulatory issues, the challenges posed by trials of different types of interventions, and the need for standardization and harmonization. The Task Force concluded with recommendations for advancing the field toward better clinical trials.

Key words

Sarcopenia clinical trial skeletal muscle frailty intervention 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Rolland Y, Czerwinski S, Abellan Van Kan G, Morley JE, Cesari M, Onder G, Woo J, Baumgartner R, Pillard F, Boirie Y, et al: Sarcopenia: its assessment, etiology, pathogenesis, consequences and future perspectives. J Nutr Health Aging 2008, 12:433–450.PubMedCrossRefGoogle Scholar
  2. 2.
    von Haehling S, Morley JE, Anker SD: An overview of sarcopenia: facts and numbers on prevalence and clinical impact. J Cachexia Sarcopenia Muscle 2011, 1:129–133.CrossRefGoogle Scholar
  3. 3.
    Cruz-Jentoft AJ, Baeyens JP, Bauer JM, Boirie Y, Cederholm T, Landi F, Martin FC, Michel JP, Rolland Y, Schneider SM, et al: Sarcopenia: European consensus on definition and diagnosis: Report of the European Working Group on Sarcopenia in Older People. Age Ageing 2010, 39:412–423.PubMedCrossRefGoogle Scholar
  4. 4.
    Fielding RA, Vellas B, Evans WJ, Bhasin S, Morley JE, Newman AB, Abellan van Kan G, Andrieu S, Bauer J, Breuille D, et al: Sarcopenia: an undiagnosed condition in older adults. Current consensus definition: prevalence, etiology, and consequences. International working group on sarcopenia. J Am Med Dir Assoc 2011, 12:249–256.PubMedCrossRefGoogle Scholar
  5. 5.
    Morley JE, Abbatecola AM, Argiles JM, Baracos V, Bauer J, Bhasin S, Cederholm T, Coats AJ, Cummings SR, Evans WJ, et al: Sarcopenia with limited mobility: an international consensus. J Am Med Dir Assoc 2011, 12:403–409.PubMedCrossRefGoogle Scholar
  6. 6.
    Muscaritoli M, Anker SD, Argiles J, Aversa Z, Bauer JM, Biolo G, Boirie Y, Bosaeus I, Cederholm T, Costelli P, et al: Consensus definition of sarcopenia, cachexia and pre-cachexia: joint document elaborated by Special Interest Groups (SIG) “cachexia-anorexia in chronic wasting diseases” and “nutrition in geriatrics”. Clin Nutr 2010, 29:154–159.PubMedCrossRefGoogle Scholar
  7. 7.
    Roman D, Mahoney K, Mohamadi A: Sarcopenia: What’s in a Name? J Am Med Dir Assoc 2012.Google Scholar
  8. 8.
    Evans WJ, Paolisso G, Abbatecola AM, Corsonello A, Bustacchini S, Strollo F, Lattanzio F: Frailty and muscle metabolism dysregulation in the elderly. Biogerontology 2010, 11:527–536.PubMedCrossRefGoogle Scholar
  9. 9.
    Subra J, Gillette-Guyonnet S, Cesari M, Oustric S, Vellas B: The integration of frailty into clinical practice: preliminary results from the Gerontopole. J Nutr Health Aging 2012, 16:714–720.PubMedCrossRefGoogle Scholar
  10. 10.
    Anton MM, Spirduso WW, Tanaka H: Age-related declines in anaerobic muscular performance: weightlifting and powerlifting. Med Sci Sports Exerc 2004, 36:143–147.PubMedCrossRefGoogle Scholar
  11. 11.
    The DJ, Ploutz-Snyder L: Age, body mass, and gender as predictors of masters olympic weightlifting performance. Med Sci Sports Exerc 2003, 35:1216–1224.PubMedCrossRefGoogle Scholar
  12. 12.
    Fiatarone MA, O’Neill EF, Ryan ND, Clements KM, Solares GR, Nelson ME, Roberts SB, Kehayias JJ, Lipsitz LA, Evans WJ: Exercise training and nutritional supplementation for physical frailty in very elderly people. N Engl J Med 1994, 330:1769–1775.PubMedCrossRefGoogle Scholar
  13. 13.
    Kosek DJ, Kim JS, Petrella JK, Cross JM, Bamman MM: Efficacy of 3 days/wk resistance training on myofiber hypertrophy and myogenic mechanisms in young vs. older adults. J Appl Physiol 2006, 101:531–544.CrossRefGoogle Scholar
  14. 14.
    Verdijk LB, Jonkers RA, Gleeson BG, Beelen M, Meijer K, Savelberg HH, Wodzig WK, Dendale P, van Loon LJ: Protein supplementation before and after exercise does not further augment skeletal muscle hypertrophy after resistance training in elderly men. Am J Clin Nutr 2009, 89:608–616.PubMedCrossRefGoogle Scholar
  15. 15.
    Goodpaster BH, Chomentowski P, Ward BK, Rossi A, Glynn NW, Delmonico MJ, Kritchevsky SB, Pahor M, Newman AB: Effects of physical activity on strength and skeletal muscle fat infiltration in older adults: a randomized controlled trial. J Appl Physiol 2008, 105:1498–1503.PubMedCrossRefGoogle Scholar
  16. 16.
    Singh NA, Quine S, Clemson LM, Williams EJ, Williamson DA, Stavrinos TM, Grady JN, Perry TJ, Lloyd BD, Smith EU, Singh MA: Effects of high-intensity progressive resistance training and targeted multidisciplinary treatment of frailty on mortality and nursing home admissions after hip fracture: a randomized controlled trial. J Am Med Dir Assoc 2012, 13:24–30.PubMedCrossRefGoogle Scholar
  17. 17.
    Abe T, Kearns CF, Sato Y: Muscle size and strength are increased following walk training with restricted venous blood flow from the leg muscle, Kaatsu-walk training. J Appl Physiol 2006, 100:1460–1466.PubMedCrossRefGoogle Scholar
  18. 18.
    Nielsen JL, Aagaard P, Bech RD, Nygaard T, Hvid LG, Wernbom M, Suetta C, Frandsen U: Proliferation of myogenic stem cells in human skeletal muscle in response to low-load resistance training with blood flow restriction. J Physiol 2012, 590:4351–4361.PubMedCrossRefGoogle Scholar
  19. 19.
    Liu CJ, Latham N: Can progressive resistance strength training reduce physical disability in older adults? A meta-analysis study. Disabil Rehabil 2011, 33:87–97.PubMedCrossRefGoogle Scholar
  20. 20.
    Pahor M, Blair SN, Espeland M, Fielding R, Gill TM, Guralnik JM, Hadley EC, King AC, Kritchevsky SB, Maraldi C, et al: Effects of a physical activity intervention on measures of physical performance: Results of the lifestyle interventions and independence for Elders Pilot (LIFE-P) study. J Gerontol A Biol Sci Med Sci 2006, 61:1157–1165.PubMedCrossRefGoogle Scholar
  21. 21.
    Rejeski WJ, Marsh AP, Chmelo E, Prescott AJ, Dobrosielski M, Walkup MP, Espeland M, Miller ME, Kritchevsky S: The Lifestyle Interventions and Independence for Elders Pilot (LIFE-P): 2-year follow-up. J Gerontol A Biol Sci Med Sci 2009, 64:462–467.PubMedCrossRefGoogle Scholar
  22. 22.
    Alley DE, Chang VW: The changing relationship of obesity and disability, 1988-2004. JAMA 2007, 298:2020–2027.PubMedCrossRefGoogle Scholar
  23. 23.
    Hulens M, Vansant G, Lysens R, Claessens AL, Muls E, Brumagne S: Study of differences in peripheral muscle strength of lean versus obese women: an allometric approach. Int J Obes Relat Metab Disord 2001, 25:676–681.PubMedCrossRefGoogle Scholar
  24. 24.
    Manini TM, Newman AB, Fielding R, Blair SN, Perri MG, Anton SD, Goodpaster BC, Katula JA, Rejeski WJ, Kritchevsky SB, et al: Effects of exercise on mobility in obese and nonobese older adults. Obesity (Silver Spring) 2010, 18:1168–1175.CrossRefGoogle Scholar
  25. 25.
    Villareal DT, Chode S, Parimi N, Sinacore DR, Hilton T, Armamento-Villareal R, Napoli N, Qualls C, Shah K: Weight loss, exercise, or both and physical function in obese older adults. N Engl J Med 2011, 364:1218–1229.PubMedCrossRefGoogle Scholar
  26. 26.
    Messier SP, Loeser RF, Miller GD, Morgan TM, Rejeski WJ, Sevick MA, Ettinger WH, Jr., Pahor M, Williamson JD: Exercise and dietary weight loss in overweight and obese older adults with knee osteoarthritis: the Arthritis, Diet, and Activity Promotion Trial. Arthritis Rheum 2004, 50:1501–1510.PubMedCrossRefGoogle Scholar
  27. 27.
    Morley JE, Malmstrom TK, Miller DK: A simple frailty questionnaire (FRAIL) predicts outcomes in middle aged African Americans. J Nutr Health Aging 2012, 16:601–608.PubMedCrossRefGoogle Scholar
  28. 28.
    Kanis JA, Johnell O, Oden A, Johansson H, McCloskey E: FRAX and the assessment of fracture probability in men and women from the UK. Osteoporos Int 2008, 19:385–397.PubMedCrossRefGoogle Scholar
  29. 29.
    Abellan van Kan G, Houles M, Vellas B: Identifying sarcopenia. Curr Opin Clin Nutr Metab Care 2012, 15:436–441.PubMedCrossRefGoogle Scholar
  30. 30.
    Kortebein P, Ferrando A, Lombeida J, Wolfe R, Evans WJ: Effect of 10 days of bed rest on skeletal muscle in healthy older adults. JAMA 2007, 297:1772–1774.PubMedGoogle Scholar
  31. 31.
    Isenring EA, Banks M, Ferguson M, Bauer JD: Beyond malnutrition screening: appropriate methods to guide nutrition care for aged care residents. J Acad Nutr Diet 2012, 112:376–381.PubMedCrossRefGoogle Scholar
  32. 32.
    Abellan van Kan G, Cameron Chumlea W, Gillette-Guyonet S, Houles M, Dupuy C, Rolland Y, Vellas B: Clinical trials on sarcopenia: methodological issues regarding phase 3 trials. Clin Geriatr Med 2011, 27:471–482.PubMedCrossRefGoogle Scholar
  33. 33.
    Seynnes O, Fiatarone Singh MA, Hue O, Pras P, Legros P, Bernard PL: Physiological and functional responses to low-moderate versus high-intensity progressive resistance training in frail elders. J Gerontol A Biol Sci Med Sci 2004, 59:503–509.PubMedCrossRefGoogle Scholar
  34. 34.
    Callahan D, Phillips E, Carabello R, Frontera WR, Fielding RA: Assessment of lower extremity muscle power in functionally-limited elders. Aging Clin Exp Res 2007, 19:194–199.PubMedCrossRefGoogle Scholar
  35. 35.
    Studenski S, Perera S, Patel K, Rosano C, Faulkner K, Inzitari M, Brach J, Chandler J, Cawthon P, Connor EB, et al: Gait speed and survival in older adults. JAMA 2011, 305:50–58.PubMedCrossRefGoogle Scholar
  36. 36.
    Ostir GV, Volpato S, Fried LP, Chaves P, Guralnik JM: Reliability and sensitivity to change assessed for a summary measure of lower body function: results from the Women’s Health and Aging Study. J Clin Epidemiol 2002, 55:916–921.PubMedCrossRefGoogle Scholar
  37. 37.
    Perera S, Mody SH, Woodman RC, Studenski SA: Meaningful change and responsiveness in common physical performance measures in older adults. J Am Geriatr Soc 2006, 54:743–749.PubMedCrossRefGoogle Scholar
  38. 38.
    Latham NK, Mehta V, Nguyen AM, Jette AM, Olarsch S, Papanicolaou D, Chandler J: Performance-based or self-report measures of physical function: which should be used in clinical trials of hip fracture patients? Arch Phys Med Rehabil 2008, 89:2146–2155.PubMedCrossRefGoogle Scholar
  39. 39.
    Kwon S, Perera S, Pahor M, Katula JA, King AC, Groessl EJ, Studenski SA: What is a meaningful change in physical performance? Findings from a clinical trial in older adults (the LIFE-P study). J Nutr Health Aging 2009, 13:538–544.PubMedCrossRefGoogle Scholar
  40. 40.
    Chale A, Cloutier GJ, Hau C, Phillips EM, Dallal GE, Fielding RA: Efficacy of Whey Protein Supplementation on Resistance Exercise-Induced Changes in Lean Mass, Muscle Strength, and Physical Function in Mobility-Limited Older Adults. J Gerontol A Biol Sci Med Sci 2013;68:682–90.PubMedCrossRefGoogle Scholar
  41. 41.
    Stimpson SA, Turner SM, Clifton LG, Poole JC, Mohammed HA, Shearer TW, Waitt GM, Hagerty LL, Remlinger KS, Hellerstein MK, Evans WJ: Total-body creatine pool size and skeletal muscle mass determination by creatine-(methyl-d3) dilution in rats. J Appl Physiol 2012, 112:1940–1948.PubMedCrossRefGoogle Scholar
  42. 42.
    Kovacheva EL, Hikim AP, Shen R, Sinha I, Sinha-Hikim I: Testosterone supplementation reverses sarcopenia in aging through regulation of myostatin, c-Jun NH2-terminal kinase, Notch, and Akt signaling pathways. Endocrinology 2010, 151:628–638.PubMedCrossRefGoogle Scholar
  43. 43.
    Cadilla R, Turnbull P: Selective androgen receptor modulators in drug discovery: medicinal chemistry and therapeutic potential. Curr Top Med Chem 2006, 6:245–270.PubMedCrossRefGoogle Scholar
  44. 44.
    Butikofer L, Zurlinden A, Bolliger MF, Kunz B, Sonderegger P: Destabilization of the neuromuscular junction by proteolytic cleavage of agrin results in precocious sarcopenia. FASEB J 2011, 25:4378–4393.PubMedCrossRefGoogle Scholar
  45. 45.
    Drey M, Sieber CC, Bauer JM, Uter W, Dahinden P, Fariello RG, Vrijbloed JW: Cterminal Agrin Fragment as a potential marker for sarcopenia caused by degeneration of the neuromuscular junction. Exp Gerontol 2012, 48:76–80.PubMedCrossRefGoogle Scholar
  46. 46.
    Ferrando AA, Paddon-Jones D, Hays NP, Kortebein P, Ronsen O, Williams RH, McComb A, Symons TB, Wolfe RR, Evans W: EAA supplementation to increase nitrogen intake improves muscle function during bed rest in the elderly. Clin Nutr 2010, 29:18–23.PubMedCrossRefGoogle Scholar
  47. 47.
    Deutz NE, Pereira SL, Hays NP, Oliver JS, Edens NK, Evans CM, Wolfe RR: Lean body mass is maintained by β-hydroxy-β-methylbutyrate (HMB) during 10 days of bed rest in older adults. Clin Nutr 2013: in press.Google Scholar
  48. 48.
    Food and Drug Administration: Guidance for Industry: Qualification Process for Drug Development Tools, accessed 12/18/12 2010.Google Scholar
  49. 49.
    Chumlea WC, Cesari M, Evans WJ, Ferrucci L, Fielding RA, Pahor M, Studenski S, Vellas B: Sarcopenia: designing phase IIB trials. J Nutr Health Aging 2011, 15:450–455.PubMedCrossRefGoogle Scholar
  50. 50.
    Lustgarten MS, Fielding RA: Assessment of analytical methods used to measure changes in body composition in the elderly and recommendations for their use in phase II clinical trials. J Nutr Health Aging 2011, 15:368–375.PubMedCrossRefGoogle Scholar
  51. 51.
    Cesari M: Frailty and aging. J Frailty Aging 2012, 1:3–6.Google Scholar

Copyright information

© Serdi and Springer-Verlag France 2013

Authors and Affiliations

  • B. Vellas
    • 1
    • 2
    • 3
  • M. Pahor
    • 4
  • T. Manini
    • 4
  • D. Rooks
    • 5
  • J. M. Guralnik
    • 6
  • J. Morley
    • 7
  • S. Studenski
    • 8
  • W. Evans
    • 9
  • C. Asbrand
    • 10
  • R. Fariello
    • 11
  • S. Pereira
    • 12
  • Y. Rolland
    • 1
    • 2
    • 3
  • G. Abellan Van Kan
    • 3
  • M. Cesari
    • 1
    • 2
    • 3
  • W. M. C. Chumlea
    • 13
  • R. Fielding
    • 14
  1. 1.Inserm UMR1027 InsermToulouseFrance
  2. 2.University of Toulouse IIIToulouseFrance
  3. 3.GerontopoleToulouse University HospitalToulouseFrance
  4. 4.University of FloridaGainesvilleUSA
  5. 5.Novartis Institutes for Biomedical ResearchCambridgeUSA
  6. 6.University of Maryland School of MedicineBaltimoreUSA
  7. 7.St. Louis University Medical SchoolSt. LouisUSA
  8. 8.University of PittsburghPittsburghUSA
  9. 9.GlaxoSmithKlineDurhamUSA
  10. 10.Sanofi-Aventis Deutschland GmbHFrankfurtGermany
  11. 11.Neurotune AGSchlierenSwitzerland
  12. 12.Abbott Nutrition R&DColumbusUSA
  13. 13.Lifespan Health Research Center, Boonshoft School of MedicineWright State UniversityDaytonUSA
  14. 14.Jean Mayer USDA Human Nutrition Research Center on AgingTufts UniversityBostonUSA

Personalised recommendations